title: Risk characterization for urinary tract infections in subjects with newly diagnosed type 2 diabetes.
abstract: OBJECTIVE
  To evaluate the risk of urinary tract infections (UTI) in subjects with newly diagnosed type 2 diabetes mellitus (T2DM).
  
  
  METHODS
  Subjects aged ≥18years and diagnosed with T2DM between 1/1/10 and 12/31/10 were identified using the MarketScan® databases, which are representative of the commercially insured US population and those with both Medicare and supplemental coverage. The index date was the first T2DM diagnosis date in 2010 (date randomly selected for those without T2DM). Subjects without T2DM were matched (1:1) by index date, age, gender, urban/rural location, and region. All subjects had continuous enrollment for 12 months before (baseline) and after (follow-up) the index date. UTI diagnosis was defined using ICD-9-CM codes. Measurements of glycemic control and body weight were not available. An adjusted logistic regression model assessed the likelihood of UTI.
  
  
  RESULTS
  A total of 89,790 matched pairs were selected. During follow-up, a UTI diagnosis was more common in subjects with T2DM than without T2DM (9.4% vs. 5.7%; p<0.0001). Recurrence of UTI was also more likely with T2DM (1.6% vs. 0.6%; p<0.0001). In a logistic regression, subjects with T2DM had a greater likelihood of UTI during follow up (adjusted odds ratio [OR]=1.54 [95% CI: 1.47-1.60]). This relationship remained after stratifying by gender.
  
  
  CONCLUSIONS
  Subjects with T2DM were more likely to experience a UTI and recurrent UTIs than subjects without T2DM during follow-up.
authors.affiliation: Georgetown University Medical Center, Washington, DC.
authors.forename: Alex Z
authors.initials: AZ
authors.lastname: Fu
authors.affiliation: Merck & Co., Inc., Whitehouse Station, NJ. Electronic address: kristy.iglay@merck.com.
authors.forename: Kristy
authors.initials: K
authors.lastname: Iglay
authors.affiliation: Merck & Co., Inc., Whitehouse Station, NJ.
authors.forename: Ying
authors.initials: Y
authors.lastname: Qiu
authors.affiliation: Merck & Co., Inc., Whitehouse Station, NJ.
authors.forename: Samuel
authors.initials: S
authors.lastname: Engel
authors.affiliation: Merck & Co., Inc., Whitehouse Station, NJ.
authors.forename: Ravi
authors.initials: R
authors.lastname: Shankar
authors.affiliation: Merck & Co., Inc., Whitehouse Station, NJ.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Brodovicz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology*; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D014552:Urinary Tract Infections / Q000453:epidemiology* / Q000209:etiology; D055815:Young Adult
keywords: Cystitis; Pyelonephritis; Recurrent infections; Risk factors; Type 2 diabetes mellitus; Urinary tract infections